Berger Franklin M's Form 4 filing
ESSA Pharma Inc. (EPIX) · filed Nov 16, 2023
- Accession no.
- 0000950170-23-064584
- Filed
- Nov 16, 2023
- Trade date
- Nov 2-3, 2023
- Filing delay
- 14 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $419.7K. It was filed 14 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Berger Franklin MCIK 0001273885 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2023 | Common Stock | PPurchaseAcquired | +60,000 | $5.35 | +$321,000 | 744,404 | Direct | |
| Nov 3, 2023 | Common Stock | PPurchaseAcquired | +16,471 | $5.99 | +$98,661.29 | 760,875 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.